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Objectives: Sleep disturbance is a common experience in fibromyalgia (FM). The field lacks a sleep specific patient
reported outcome (PRO) measure developed and validated in a FM population. The study objective is to gain an
in-depth understanding of sleep in FM and to develop a PRO measure of it.
Methods: Research involved the following stages: 1) A literature review conducted to identify key concepts
associated with FM patient experience of sleep and PRO measures that have been used to assess this; 2) Qualitative
interviews with therapeutic area experts; 3) Focus groups with FM patients who experienced sleep disturbance;
4) Development of a conceptual framework and the Fibromyalgia Sleep Diary (FMSD); and 5) Cognitive interviews
with patients to explore content validity of the FMSD.
Results: The literature review and expert interviews supported sleep disturbance being an important aspect of the
FM patient experience, and underscored the need for a new FM specific sleep PRO measure. Results from the focus
groups demonstrated that FM patients experience sleep disturbances that they attribute to their FM symptoms,
such as pain and stiffness, confirming the importance of understanding more about sleep changes. Aspects of
sleep raised by FM patients included poor sleep quality and insufficient quantity including difficulty with falling
asleep, getting comfortable, and staying asleep; restlessness; light sleep; not feeling rested upon awakening; and
difficulty starting the day. Cognitive interview results showed that the 8-item FMSD, developed to reflect the
concepts identified above, was relevant to FM patients with content that was interpreted as intended.
Conclusions: The FMSD was developed in line with the recommendations of the FDA PRO guidance and ISPOR
PRO Task Force. The qualitative evidence generated thus far strongly supports the content validity of the FMSD as a
PRO measure of sleep disturbance in FM populations. Psychometric evaluation of the FMSD to demonstrate
reliability, validity and sensitivity to change is recommended as a next step.
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Fibromyalgia (FM) is characterized by chronic widespread
pain and tenderness [1]. Common associated symptoms
include fatigue, mood disturbance, and sleep problems
[2]. In a patient Delphi Panel run as part of the Out-
come Measures in Rheumatology (OMERACT) project,
sleep problems appeared as the fourth most important* Correspondence: Claire.Burbridge@pfizer.com
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unless otherwise stated.domain to FM patients with 92% of patients reporting
that this domain should be assessed in FM clinical trials
[2,3]. In another study, published by Arnold and col-
leagues [4], patients with FM reported that disrupted
sleep was a common symptom associated with FM.
Most patients indicated that both fatigue and pain were
directly related to the poor quality of their sleep. In
OMERACT 9 (the 9th annual meeting) [2], sleep dis-
turbance was noted as one of a core set of domains
considered essential for assessment in FM clinical trials.
The impact FM has on sleep was defined in OMERACTal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ing sleep [2].
The Food and Drug Administration (FDA) issued a
guidance document describing the necessary evidence
for a Patient Reported Outcome (PRO) instrument to sup-
port label claims [5], which includes the evaluation of con-
tent validity as a key recommendation (i.e. assessment and
documentation of how the PRO measures the concepts
relevant to the population). Recently, the International So-
ciety for Pharmacoeconomics and Outcomes Research
(ISPOR) PRO Task Force published five “good research
practices” that are crucial steps in establishing and docu-
menting the evidence of content validity for new PRO
instruments [6]. These are: 1) identification of the PRO
measurement concept and the context of use; 2) develop-
ment of the qualitative concept elicitation protocol; 3)
qualitative concept elicitation data collection among the
population of interest (i.e. a pre-specified patient popu-
lation); 4) analysis of the qualitative data; and 5) docu-
mentation of methods used and results of the validity
assessment of the content of the PRO measure (e.g., in-
structions, items, response options, recall period). Current
standards focus on the need for concrete evidence of the
direct link between the patient perspective and the con-
cept and item coverage in a PRO measure.
The objective of this research study was to gain an in-




















Figure 1 Study flow diagram.PRO measure of sleep disturbance in FM. These objec-
tives were met by employing a multi-staged approach
that encompassed qualitative and instrument develop-
ment work that is in line with current PRO instrument
development recommendations [6,7]. This included the
following stages: 1) a literature review; 2) interviews with
therapeutic experts; 3) focus groups with FM patients; 4)
development of a conceptual framework and drafting of
a PRO measure; 5) cognitive interviews to test the new
PRO measure. Each stage provided data that informed
subsequent stages (see Figure 1). Each stage is presented
in turn with the rationale, methods, and results.
Stage 1 Literature review
Rationale
A targeted literature review was conducted to identify
types of sleep disturbances in FM and any existing PRO
measures used to evaluate this concept in the FM popu-
lation. Evidence from the literature review was used to
determine the need for a new measure of sleep in FM,
to develop qualitative interview guides for the interviews
with experts and the focus groups with FM patients, as
well as to inform the conceptual framework.
Methods
The literature review was conducted in MEDLINE and
EMBASE. Terms used in the search included terms forStage 5:
Cognitive interviews to test 
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ard combination used to identify PRO measures (such as
interview, questionnaire, rating scale, instrument, out-
comes). In addition, these searches were supplemented
by a review of FM or sleep-specific PRO measures listed
in the PRO research database PROQOLID, as well as a
review of clinical trials that targeted adult FM patients,
assessed sleep outcomes, and were listed in the clinical
trial search engine provided by the U.S National Insti-
tutes of Health (NIH; http://clinicaltrials.gov).
The search terms can be found in the Additional file 1
online.
Results
Four hundred and forty-two abstracts were reviewed for
relevance. Excluded abstracts consisted of those that did
not discuss key concepts related to sleep and FM, or in-
cluded pediatric patients as all or part of the population.
Seventy-nine articles were retrieved for full text review
and categorized as observational studies (n = 25), review
articles (n = 21), case–control studies (n = 10), instrument
evaluations (n = 9), qualitative studies (n = 6), cross-
sectional studies (n = 3), clinical trials (n = 4), and a
pooled analysis (n = 1). Additionally, a search of the web-
site clinicaltrials.gov identified 45 ongoing clinical trials in
FM that included a sleep outcome used in a review of
available PRO measures.
The text of the 79 articles was reviewed to identify
mentions of constructs for sleep and other fibromyalgia
symptoms. Across the articles reviewed, the sleep spe-
cific concepts most frequently noted as being a compo-
nent of FM (i.e., mentioned in >20% of the 79 articles)
included: sleep disturbance (characterized as arousals,
sleep stage changes, wake after sleep onset) [8]; poor
quality of sleep [9,10]; insufficient sleep duration or quality
[11]; daytime dysfunction [12]; awakening unrefreshed
[13]; and low sleep efficiency [14]. Other sleep specific
concepts that were mentioned less frequently included
difficulty getting comfortable, habitual snoring, and day-
time somnolence. The six qualitative studies reviewed
endorsed sleep disturbance being part of the FM patient
experience [3,4,15–18].
In addition, a wide variety of PRO measures that have
been used to assess sleep in FM populations were iden-
tified. The most frequently utilized were the sleep item
of the Fibromyalgia Impact Questionnaire (FIQ), a
FM-specific measure [19]; the Pittsburgh Sleep Quality
Index (PSQI) [20]; the MOS-Sleep Scale [21]; the Epworth
Sleepiness Scale [22]; and the Jenkins Scale for Sleep [23].
Results for the sleep outcomes included in the 45 clinical
trials listed on the NIH search engine were similar to the
results of the literature review; 26 trials included the FIQ,
11 trials included the MOS sleep scale, seven trials in-
cluded the Multidimensional Fatigue Inventory [24], andfour trials included the PSQI. In addition the use of a daily
sleep log diary was often reported, particularly in the
clinical trials.
The history of the sleep specific PRO measures was
explored to ascertain if any met the FDA guidance re-
quirements for PRO development [5], including qualita-
tive research conducted in the target population (i.e.,
patients with both FM and sleep disturbances included
in both concept elicitation and cognitive interviewing),
evidence of final content validity determined through
quantitative analyses (e.g., Rasch models, confirmatory fac-
tor analysis), adequate psychometric characteristics, and
score sensitivity to change and interpretability. The search
revealed that none of the sleep specific or more generic
PRO measures mentioned above had development and
validation information available to demonstrate their rele-
vance as a sleep measurement tool specifically for the FM
population. The one general FM measure (FIQ) was ex-
cluded as it does not focus specifically on sleep. Thus,
based on this literature review and the current standards
in the field for development of PRO measures, it became
apparent that, despite the importance of sleep disturbance
in FM, the field was lacking a sleep specific measure that
has been developed and validated for FM populations.
Stage 2 - Interviews with therapeutic area experts
Rationale
Clinical input about the condition or disease area is rec-
ommended [5] to gather information about the clinical
aspects of the condition as well as providing a starting
point for discussions with patients. Interviews with four
therapeutic area experts in FM were conducted to con-
firm the key findings of the literature review, and to pro-
vide information around how patients with FM discuss
their sleep issues. This information was then used to in-
form the interview guide for the focus groups with FM pa-
tients. In addition to completing formal interviews with
experts, two co-authors (LMA and TR) were involved in
study decisions on an on-going basis.
Methods
A pool of US-based experts was sent a recruitment e-mail
with an overview of the study and information on the role
of therapeutic area experts. The e-mail requested that in-
terested parties return a background questionnaire that
asked about degree, primary clinical specialty, number of
years in practice, percentage of time spent in clinical prac-
tice, and number of FM patients seen per week. The ex-
perts were then selected to participate in the one-time
interview based on level of experience with treating the
population of interest, as determined by responses to the
background questionnaire as well as their interest and
availability. A semi-structured interview guide was used to
facilitate the expert interviews, which focused on topics
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sleep disturbance on FM patient’s daytime function.
They were also asked about experiences with assessing
sleep using quantifiable instruments. Interviews were
audio-recorded, and summary tables were created by
listening to the audio-recorded interviews and summar-
izing the responses for each expert. These tables were
manually reviewed to analyze the feedback across inter-
views and identify key themes.
Results
Four experts completed the one-on-one telephone inter-
views. They comprised three physicians (a psychiatrist, a
rheumatologist and a neurologist with a specialty in sleep
medicine) and one registered nurse. They had an average
of 14.5 years of experience working with patients who
have FM (range: 3 to 25 years), reported seeing approxi-
mately 25–30 FM patients per week (range: 10–60), and
reported practicing in multiple settings, including private
and academic clinical practices and research clinics (e.g., a
sleep laboratory).
Experts reported that a substantial number of FM pa-
tients spontaneously raise the issue of disturbed sleep.
When not specifically raised by the patients, all clinicians
reported probing to see if sleep disturbance is a problem.
Not surprisingly the experts used more technical descrip-
tions (e.g., non-restorative sleep, delayed sleep onset, sleep
disturbance or inability to sleep, feeling un-refreshed),
but their patients use a variety of descriptive expressions
such as, feeling exhausted, not having a good night’s
sleep or a deep/restful sleep, awakening during the night
due to light sleep, and having difficulty falling back
asleep once awake. They noted that patients often dif-
ferentiated between sleep quality and sleep quantity
with the former being more descriptive (i.e., disturbed
sleep, poor quality sleep, a feeling of being non-rested)
and the latter being more quantitative (i.e., the number
of hours a patient reported sleeping or being in bed,
number of awakenings).
The expert panel reported using PRO measures of pain
and sleep in order to quantify patient issues, or as part of
the requirements for clinical trials. For example, a 0 to 10
visual analogue scale on sleep quality, the Epworth Sleepi-
ness Questionnaire, and the SF-36 (although not a sleep
specific measure) were identified; however, experts noted
that these were not specific to FM, nor were they con-
sistently effective in clinical trials or practical in clinical
practice either because of lack of specificity or being
cumbersome to use and score.
In summary, the findings from this portion of the
research supported sleep disturbance being an important
aspect of FM that would benefit from measurement
tools that are more focused on the FM patients’ experi-
ence of sleep.Stage 3 - Focus groups
Rationale
Development of a PRO measure must be based on pa-
tients’ perceptions or thoughts around the concept of
interest; this is the direct link from the patient voice to
the measure [5]. Focus groups provide an opportunity to
gather qualitative data in a conversational setting, allow-
ing for group dynamics to facilitate a broad-ranging dis-
cussion in the population of interest.Methods
Five focus groups consisting of a total of 36 patients
with FM and documented sleep disturbance associated
with FM (as noted via chart review and verification by
the clinical site during recruitment), were held at three
different community-based clinical sites in the United
States including two in California and one in Texas. The
sample was a convenience sample with sites recruiting
participants using eligibility criteria designed to align with
key criteria in the study sponsor’s FM clinical trial popula-
tions. This study was reviewed and approved by an IRB
(Ethical and Independent Review Services), all participants
provided written informed consent prior to the focus
group discussion session, and patient confidentiality and
good research practices were followed throughout the
course of the study.Inclusion/exclusion criteria for the focus groups
Potential participants were assessed by clinicians at each
site to determine if they met inclusion and exclusion cri-
teria. Participants were required to: be 18 years of age or
older; meet the American College of Rheumatology (ACR)
criteria [1] for FM as documented in patient charts; report
disturbed sleep at least three times per week for at least
one month in the three months prior to screening; and to
read, speak and understand English. Participants were
allowed but not required to be receiving current treatment
for FM.
Patients were excluded if: they had a history of a sleep
or circadian rhythm sleep disorder as a result of a medical
condition other than FM (such as restless leg syndrome,
narcolepsy, sleep apnea, or phase advance or delay syn-
dromes) within the past five years; had been on night or
rotating shift work, had traveled across more than four
time zones in 14 days prior to the focus group, or experi-
enced regular disruptions during the night from another
cause (e.g., care for dependents); had severe pain due to
other conditions or with any widespread inflammatory
musculoskeletal disorder, rheumatic disease (other than
FM), active infections, untreated endocrine disorders, or
somatoform disorders; or had uncontrolled, severe or un-
stable depression that could have interfered with the con-
duct of the study.
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Groups were moderated by an interviewer trained in focus
group techniques and participants were remunerated for
their time. A semi-structured discussion guide was devel-
oped specifically for this study based on the literature re-
view and the discussions with experts (see Additional file
2 online). The sessions were audio-recorded with partici-
pant permission and later transcribed for analysis. The
topics, questions, probes, and group activities were de-
signed to focus broadly on patients’ perspectives of their
FM as it related to their experiences with sleep, their over-
all experiences with sleep, the frequency and variability of
symptoms, and the perceived importance of their symp-
toms or experiences. Focus groups lasted approximately
1½ to 2 hours.
After the completion of each focus group discussion,
participants completed a brief set of questionnaires to
permit description of the characteristics of the partici-
pant sample. These questionnaires included the (FIQ)
evaluating FM symptoms and impact over the past week,
numerical rating scales (NRS) evaluating pain, sleep dis-
turbance and tiredness due to FM over the past week,
and the Subjective Sleep Questionnaire (SSQ) which
asks more detailed questions about the previous night’s
sleep (time to fall asleep, number of awakenings, time
awake during the night and length and quality of sleep).
All participants had completed a socio-demographic form
immediately before the focus group began. In addition,
sites completed a brief clinical form for each participant
describing their history of fibromyalgia (length of time
with diagnosis, key symptoms, and current medications).
Analytic approach
Qualitative analysis techniques similar to those outlined
by the International Society for Pharmacoeconomics andTable 1 Saturation grid of sleep disturbance discussion in foc
Concept of Sleep Disturbance FG 1 (n = 9) FG 2 (n =
Trouble falling asleep X X
Wake after sleep onset X X
Tossing and turning X X
Waking up due to discomfort X X
Restfulness of sleep X X
Trouble staying asleep X
Unrested X X
Never fully asleep X
Time to fall asleep X
Length of sleep X
Cyclical sleep X
Level of Energy X X
Unrefreshed X
1An “X” indicates the concept was endorsed by one or more patients within the focOutcomes Research (ISPOR) PRO Good Research Prac-
tices Task Force Report Part 1 were followed [6]. Qualita-
tive data (i.e., transcriptions of discussions) were organized
with a qualitative analysis software program, ATLAS.ti
(version 5.0), in order to conduct a systematic analysis of
the transcripts. A set of thematic codes were drafted based
on the interview guide, which was informed by the litera-
ture review and expert interviews. This list was used to
code the transcript data, and to record new themes arising
from the focus group analysis, thus capturing the major
topic areas of discussion in the focus groups. After the
coding and cleaning (removal of all personal identifiers) of
transcripts was completed, they were analyzed by review-
ing the specific quotes by code in order to synthesize and
summarize the results, as well as to assess saturation of
concepts. The primary focus of this qualitative analysis
was to identify themes around the experience of sleep dis-
turbance in FM populations, and the qualitative results
were summarized by post-hoc assessment of endorsement
of concepts per focus group (Table 1) and reporting of the
number (and percentage) of participants that endorsed
each concept. Saturation is necessary prior to instrument
development and is reached when similar themes arise
across focus groups and no substantially new information
is uncovered in later focus groups [25].
Results
Although 36 participants were consented and interviewed,
two were found to be ineligible after study completion
due to self-reported co-morbid disorders (multiple scler-
osis and sleep apnea). All data for these two patients were
excluded from analysis; therefore, the sample size for this
study is 34.
Participants were primarily female (n = 30, 88.2%) and
white (n = 25, 73.5%). The mean age was 47.8 (±11.9)us groups1















Table 3 Focus group and cognitive interview sample









Sleep disturbance in the past week 6.4 (1.9); 7.4 (1.4);
(“0 “no sleep disturbance” to 10 “worst
possible”)
(1, 10) (6, 10)
Pain in the past week 6.9 (1.8); 7.3 (1.7);
(“0” no pain to “10” worst possible pain) (2, 10) (3, 10)
Tiredness in the past week 7.4 (1.8); 7.6 (1.7);
(0”not tired to “10” extremely tired) (2, 10) (4, 10)
Time taken to fall asleep last night
(in minutes)
74.5 (69.4); 118.7 (147.4);
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disabled; of these 16, more than half (n = 10, 62.5%) felt
this was due to FM. See Table 2 for demographic charac-
teristics and Table 3 for self-reported sleep disturbances
experienced within the previous week as reported on the
post-focus group questionnaire.
Ninety-seven percent (n = 33, 97%) reported disturbed
sleep as a result of FM, mostly attributed to the pain and
stiffness, and often drawing negative comparisons be-
tween their current sleep and their sleep prior to having
symptoms and being diagnosed with FM. One partici-
pant noted:
“I said I used to sleep really well. I could sleep all the
way through, like before I was diagnosed withTable 2 Focus group and cognitive interview sample








Age (years) 47.8 (11.9); 22-70 51.4 (10.1); 27-64
Gender (n, % female) 30 (88.2%) 14 (93.3%)
Ethnicity (n, % Hispanic or Latino) 8 (23.5%) 0 (0%)
Race* (n, %)
White 25 (73.5%) 11 (73.3%)
Black or African American 1 (2.9%) 3 (20.0%)
Asian 2 (5.8%) 1 (6.7%)
Native Hawaiian or other Pacific
Islander
4 (11.7%) 0 (0%)
American Indian or Alaska Native 1 (2.9%) 0 (0%)
Other1 6 (17.6%) 0 (0%)
Employment Status* (n, %)
Employed, full-time 7 (20.5%) 4 (26.7%)
Employed, part-time 9 (26.4%) 1 (6.7%)
Homemaker 2 (5.8%) 1 (6.7)
Student2 1 (2.9%) 0 (0%)
Unemployed 7 (20.5%) 3 (20.0%)
Retired 3 (8.8%) 2 (13.3%)
Disabled 9 (26.4%) 6 (40.0%)
Other2 2 (2.8%) 0 (0%)
Unemployed or Disabled
due to Fibromyalgia (n, %)
Yes3 10 (62.5) 7 (77.8%)
No4 6 (37.5%) 2 (22.2%)
*Participants could select more than one response option.
1Six participants selected other and described themselves as: “Mexican
American,” “Russian Jew Spanish,” “Mexican,” “Hispanic/Portuguese,”
“Hispanic,” and “Mexican.”
2“Pastor”.
3One participant checked, “homemaker” and marked, “Yes” for, “If unemployed
or disabled, is this due to your fibromyalgia.”
4One participant checked, “employed part time” and marked, “no” for “If
unemployed or disabled, is this due to your fibromyalgia.”
(5, 240) (5, 600)
Time spent sleeping last night
(in minutes)
324.0 (76.8); 224 (122.7);
(180, 510) (0, 510)
Number of times awoken last night,
(mean, sd)
2.5 (1.5); 3.3 (2.1);
(0, 5) (0, 6)
Time spent awake after falling asleep
last night (in minutes)
71.4 (166.2); 154 (127.9);
(0, 960) (0, 390)
Quality of sleep 5.1 (2.3); 2.7 (2.3);
(“0” very poor to “10” excellent) (0, 10) (0, 6)fibromyalgia or, you know, even having all the
symptoms. I could sleep through the storm. Now
anything will wake me up.” (FG 2)
Generally speaking, participants identified a good night’s
sleep as being uninterrupted or with minimal interrup-
tions due to physical discomfort. Disturbances relating to
both sleep quality and sleep quantity were raised as issues,
and it was notable that participants did not consider
sleep quality to be directly related to the perceived
quantity of sleep. Eleven (32%) described insufficient, or
simply not enough, sleep as being part of their sleep ex-
perience with FM.
“Maybe five, yeah, four or five hours, and there’s
many times I wake up at 3:00, 4:00. And that’s not
enough…” (FG 1)
Sleep quality was discussed as being the “type” of sleep
experienced, with almost one-third (n = 10, 29%) of par-
ticipants describing not having a good night’s sleep, not
experiencing deep sleep, and reporting feelings of rest-
lessness during sleep. They reported awakening during
the night due to light sleep or for various other reasons
relating to their FM (e.g., pain, sleep in a warped pos-
ition, discomfort).
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never get comfortable, your neck is never in the right
position…” (FG 5)
“I just know I wake up, and I-and I’m like, oh, toss
and turn. And then I only sleep on my shoulder for
maybe like 30 minutes.” (FG 2)
Participants discussed difficulty falling asleep and stay-
ing asleep, “Falling asleep, that takes forever”. Descrip-
tions included the time it took to fall asleep, being “up
every hour,” “frequently waking up,” having difficulty
getting back to sleep once awake, being up all night, and
awakening earlier than desired.
“I can, initially, go to sleep, but it’s staying asleep that’s
very hard. And then, I got to sleep tired and I wake up
exhausted, and it’s frustrating.” (FG 4)
“I've become really restless throughout the night. I have
trouble falling asleep. And then, I'm kind of in that
dozed, as you described, state. You’re never fully
asleep. You’re never fully awake. And I can toss and
turn and just shift and move.” (FG 4)
Almost half (n = 15) described problems when awaken-
ing for the final time in the morning. The most common
problems faced when waking up were a feeling of exhaus-
tion, pain and stiffness, and an inability to get out of bed
in the morning or get their days started without delay.
“And then you’re staying in bed. I pretty much stay in
bed all day.” (FG 5)
“Even if I do get a good night’s sleep, let’s assume like
six hours, a good night’s sleep, and I wake up at 6 in
the morning, I can’t function to do anything until
12:00 noon. I can’t do the dishes, I can’t do anything,
it’s like you’re just-you’re lethargic, you know.” (FG 5)
As part of the review and analysis of the focus group
data, participant wording around sleep disturbance was
grouped into broader categories. A saturation grid was de-
vised to examine the following concepts in sleep: trouble
falling asleep, wake after sleep onset, tossing and turning,
waking up due to discomfort, trouble staying asleep, un-
rested, never fully asleep, time to fall asleep, length of
sleep, cyclical sleep (patterns of falling asleep and waking),
and feeling unrefreshed (see Table 1).
An iterative process was used to develop a conceptual
framework of sleep disturbance in FM, presenting the
concepts around sleep disturbance that were reported by
the patients as being an important part of the FM experi-
ence (see Figure 2).Stage 4: Conceptual framework and instrument
development
The conceptual framework, based on the results of the
literature review, expert interviews, and patient focus
groups, informed the development of a daily sleep diary,
the Fibromyalgia Sleep Diary (FMSD). An iterative process
was used to develop the FMSD, including consideration of
results from all stages of this research project and input
from all authors. The endorsement of concepts from the
focus group was considered (Table 1), in addition to the
information about the concepts found within the literature
review stage and the expert interview stage (Table 4). The
terminology used by the participants during the focus
groups was utilized when drafting the content of the
FMSD. The FMSD comprises eight items that reflect the
sleep disturbances highlighted in the conceptual frame-
work, with wording of the items based on terminology
used by participants during the focus groups. Items assess
difficulty with falling asleep, restlessness of sleep, difficulty
getting comfortable, difficulty staying asleep, degree of
deep sleep, degree of being rested when waking up for the
day, difficulty with beginning the day, and degree of hav-
ing enough sleep during the previous night. Responses are
on a 0–10 scale with anchors at each end. The FMSD was
designed to be completed daily in the morning after final
awakening, to aid accurate recall of sleep disturbances, via
the telephone using an Interactive Voice Recognition
(IVR) System.
A daily diary format was chosen for multiple reasons.
During the focus groups, participants were able to de-
scribe the difference between a night with mild, moderate,
or severe sleep disturbance, as well as bad nights versus
good nights, indicating day-to-day variability. This diary
format with daily recall also matches more objective sleep
measures that are often used in clinical trials of insomnia
and other sleep disturbances. It avoids the difficulties asso-
ciated with weekly recall such as 1 or 2 bad nights differ-
entially influencing the weekly recall.
Stage 5 - Cognitive interviews
Rationale
Cognitive interviewing is used to assess the comprehen-
siveness, relevance, understanding, interpretation and read-
ability of a PRO from the perspective of those intended to
complete the measure. The next step of this development
process was to conduct cognitive interviews to test the
FMSD in FM patients.
Methods
Fifteen one-on-one cognitive interviews with FM patients
who experienced sleep disturbance were conducted at
two community clinical sites located in New Jersey and
California. The study was reviewed and approved by Eth-
ical and Independent Review Services IRB, all participants
How difficult was 
it to get  
comfortable? 
How rested were 
you when you 
woke up for the 
day?
How difficult was it 
to begin your day?
How difficult was it 
to fall asleep?
How difficult was it 
to stay asleep?















Did you have 
enough sleep?
Figure 2 Conceptual framework for sleep disturbance in fibromyalgia.
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and patient confidentiality and good research practices
were followed throughout the course of the study.
Inclusion/exclusion criteria
The inclusion and exclusion criteria for the cognitive in-
terviews were the same as those criteria for the focus
group study as outlined above. Clinicians at each site com-
pleted chart reviews and recruitment interviews to ensure
adherence to the inclusion/exclusion criteria. Sites com-
pleted a similar clinical form as well.
Procedures
Prior to the interview, participants completed the FMSD.
To simulate the IVR system administration, during the
interview participants completed the FMSD by calling astudy team member who read the items and response
options using a script and allowed the participant to se-
lect responses by pressing the telephone keypad.
Participants then engaged in a standardized retrospect-
ive cognitive interview involving detailed questions about
each item on the diary. This focused on comprehension
and understanding of the FMSD items, including rationale
for answer selection, potential variability of answer, under-
standing of the recall period, questions around redundant
items and potential wording changes, and review of alter-
native response options. Alternative response options
included using the “worst possible symptom and best pos-
sible symptom” as anchor points as well as “no difficulty
and worst possible difficulty”. In addition, the interview
assessed ease of completion, comprehensiveness, and rele-
vance of the diary overall and the IVR format.











FMSD Item Support from
cognitive
interviews (n = 15)4
Difficulty falling asleep,
initiating
Falling asleep ✓ ✓ ✓ How difficult was it to fall
asleep last night?
15/15










Staying asleep ✓ ✓ ✓ How difficult was it to stay
asleep last night?
14/14







✓ ✓ ✓ How rested were you when






✓ ✓ ✓ How difficult was it to begin
your day?
15/15
Quantity of sleep Sufficient
sleep
✓ ✓ ✓ Did you have enough sleep
last night?
15/15
1Identified as important in existing research.
2Concept was endorsed by experts during the therapeutic area expert interviews.
3Concept was endorsed by patients in the focus group discussions.
4Patients understood the item meaning, understood response scale, and were able to select a response.
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ipants completed: the FIQ, the weekly pain NRS, tired-
ness NRS, and the SSQ.
Analytic approach
A content analysis approach was used to evaluate the in-
formation gathered during the cognitive interviews. The
analysis was based on recall, notes taken by the inter-
viewer, audio recordings, and transcripts. The transcribed
cognitive interviews were organized with the same qualita-
tive analysis software program, ATLAS.ti (version 5.0),
used for Stage 4, in order to conduct a systematic analysis
of the transcripts. The qualitative analysis was organized
by areas of discussion. A coding dictionary was developed
to organize the data and be able to better cluster discus-
sion of the FMSD items. The codes were utilized to iden-
tify specific areas of discussion about the diary across
participants. For example, an instructions code captured
all discussion around participants’ understanding of the
FMSD instructions. Output of the coded data was created
to permit examination of the transcribed interview data to
evaluate participant responses regarding their comprehen-
sion, relevance of the FMSD to their experiences, and ease
or difficulty with selecting a response for each item on the
FMSD. Participant preference for the various alternate op-
tions that were presented was also reviewed. The results
were used to assess the content validity of the FMSD.
Results
The majority of the 15 participants were female (93.3%)
with a mean age of 51.4 (10.1) years with a range of 27to 64 years; 73.3% identified themselves as white, 20.0% as
black or African American, and 6.7% Asian. Most partici-
pants assessed their overall health as either “fair” (40.0%)
or “poor” (40.0%), with two selecting “good” (13.3%) and
one “very good” (6.7%). See Tables 2 and 3 for self-
reported sleep disturbances.
The FMSD instructions were well understood. Seven
of the eight FMSD items were interpreted as intended
by all participants. One participant misunderstood the
item “How difficult was it to stay asleep?” confusing it
with difficulty falling asleep. Participants reported no dif-
ficulty with the response options, despite some shifts in
direction of the response scale between items (e.g., the
response indicating the least amount of impact changes
between 0 and 10 depending on the item). In general,
the original anchors of “not at all” and “extremely” on a
0 – 10 point scale were preferred to the alternatives that
were presented. All participants understood the time
frame within each question and reported this as being ap-
propriate to the item.
During discussion of the FMSD item that asks about be-
ing rested when waking for the day, participants were
asked to consider an alternate term “refreshed.” Responses
varied as to whether the two terms were the same or dif-
ferent in meaning. Participant comments did reveal a
theme around the term “refreshed” being viewed as an
overly positive term and seen as beyond normal rest;
therefore, the original wording (i.e., rested) was retained.
“‘Rested’ means that it, the nervous system has calmed
down, that you’re um, calm, that there’s nothing there
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brought to bed with you is gone away. You’re rested.
Um, ‘refreshed’ is more like um, it’s beyond rested. You
are rested and you are rejuvenated. There’s a ‘plus’
factor in there, just a little more, to me.”
Two alternate phrasing options for the FMSD were
presented: starting items with the phrase “Last night,”
and presenting the items as statements rather than ques-
tions. Presenting items as questions (as opposed to the
alternative of statements) was preferred. The majority of
participants did prefer adding the phrase “last night” to
applicable FMSD items; therefore, “last night” was added
to the applicable items (i.e., 1–5 and 8). This was the
only change made to the FMSD following the cognitive
interviews.
Overall, the FMSD was found to be clear, comprehen-
sible and relevant to patients. Participants were able to in-
terpret the items as intended, understood the terminology
used, and agreed that it captured the sleep experiences as-
sociated with FM. In addition, participants found that the
response scales and recall period were appropriate, and
that it was relatively easy to complete through the simu-
lated IVR system.
Table 4 presents a summary of the support for each item
in the FMSD from the various stages of the research.
Conclusions and discussion
Sleep disturbance has clearly been identified as an import-
ant part of the experience of fibromyalgia among patients,
as seen in the literature [2–4], Moreover, the qualitative
work with both patients and experts in this study con-
firmed the findings from the literature that the main sleep
disturbances experienced within FM relate to problems
falling asleep, staying asleep (disturbed sleep and frequent
awakenings), how a person feels upon awakening, and the
amount of sleep obtained.
The many PRO measures that have been used to as-
sess sleep in FM were compared against the recommen-
dations from the FDA PRO guidance [5] and ISPOR
PRO task force [6]. In general, these PRO measures were
nonspecific to FM, and or sleep, and lacked the neces-
sary qualitative evidence to demonstrate relevance to the
unique features of sleep disturbance in the FM population.
This included a lack of patient input into item develop-
ment, no demonstration of FM patients’ comprehension
of the instruments, and lack of validation in the FM popu-
lation. Importantly almost all of them were not developed
specifically for FM patients
To fill this need, the FMSD was developed, in line with
the recommendations in the FDA PRO guidance [5] and
of the ISPOR PRO Task Force [6]. The concepts evaluated
within the FMSD were identified from in-depth qualitative
work with FM patients, and items were developed usingterminology that was derived from the language patients
used during the focus groups. Further qualitative work
with patients was conducted through cognitive interviews
to assess the content validity of the measure. Results
showed that the FMSD items were relevant to the FM
population with content that was interpreted as intended,
and questions and response options that patients under-
stood and could answer.
A limitation of this research is that the FMSD focuses
specifically on PRO measurement of sleep disturbance in
FM populations; therefore, it is recommended that the
FMSD be used as part of a wider measurement strategy
for patients with FM, particularly in the context of clin-
ical trials. Sleep disturbance in FM has been shown to
have an impact on the functioning and health-related
quality of life for FM patients [3], which was confirmed
in the focus groups conducted in the early stages of this
work. These broader areas of daily functioning and qual-
ity of life are an important part of evaluating FM as a
whole, as they are impacted by all symptoms in FM and
not simply by sleep disturbance. Further limitations in-
clude the use of a convenience sample focused on clin-
ical trial like eligibility criteria.
The qualitative evidence generated thus far strongly
supports the content validity of the FMSD as a PRO meas-
ure of sleep disturbance in FM populations. However, add-
itional study of the FMSD is necessary to explore further
the psychometric properties of this tool, as outlined within
the recommendations for PRO development [5].
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